NL
DE
The Hematology-Lymphoma Biobank plans to collect blood, saliva, serum and cell-free DNA from every lymphoma patient, in addition to the residual material available from the Pathology department (tumor tissue), the Hematology department and the Laboratory of Hematology (bone marrow, peripheral blood and tumor tissue). In recent years, much progress has been made in the knowledge surrounding the processes involved in the development and progression of lymph node cancer and the response to therapy. The aim and ambition of HEMLYM is to improve the diagnosis and treatment of patients with lymphoma.
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Quality certificate for the PBMC isolation method and cfDNA extraction method
8 August 2023Last year the Radboud Biobank participated for the first time in the IBBL Biospecimen Proficiency Testing program; an external quality assessment tool to verify the precision and accuracy of biospecimen testing methods and the efficiency of processing methods.
read more
TETRO-trial
30 March 2023The TETRO-trial is a study on a new treatment for compulsive/obsessive-compulsive disorder.
read more
Archipelago
30 March 2023Archipelago of Ovarian Cancer Research (AOCR) is a national platform for centralizing and expanding scientific research into ovarian cancer.
read more
Theme Biobank and collections of Health RI launched a new project to develop a novel Dutch Biobank Standard
30 March 2023In February 2023 the theme Biobanks and Collections of Health-RI launched a new project entitled: “Dutch biobanking standard: towards harmonized, evidence-based collection, processing and storage of human biomaterials”.
read more
Health-RI receives definitive follow-up funding from the National Growth Fund
30 March 2023The full funding of a total of 69 million euros has been definitively awarded to Health-RI, the national health data infrastructure for research and innovation.
read more